Research Topics
| Brian P O'SullivanSummaryAffiliation: University of Massachusetts Medical School Country: USA Publications
| Collaborators
|
Detail Information
Publications
Cystic fibrosis heterozygotes do not have increased platelet activationInge Tarnow
Department of Physiology and Biochemistry, University of Copenhagen, The Faculty of Life Sciences, Frederiksberg C, Denmark
Thromb Res 121:159-62. 2007..Platelet hyperreactivity in CF heterozygotes would be an important cardiovascular risk factor, since approximately 1 in 25 Caucasians is a CF carrier...- Pulmonary complications of systemic vasculitidesBrian P O'Sullivan
Department of Pediatrics, University of Mass Memorial Health Care Worcester, MA 01655, USA
Paediatr Respir Rev 13:37-43. 2012..A diagnosis often can be made on the basis of clinical presentation and serologic studies, but biopsy of skin, nose, kidney, or lung may be necessary to ascertain the precise syndrome... - Platelet activation in cystic fibrosisBrian P O'Sullivan
Department of Pediatrics, UMass Memorial Health Care and University of Massachusetts Medical School, Worcester, MA 01655, USA
Blood 105:4635-41. 2005..Our findings may account, at least in part, for the beneficial effects of ibuprofen in CF... - Cystic fibrosisBrian P O'Sullivan
Department of Pediatrics, University of Massachusetts Medical School, Worcester, MA 01655, USA
Lancet 373:1891-904. 2009..We review clinical care for cystic fibrosis and discuss recent advances in the understanding of its pathogenesis, implementation of screening of neonates, and development of therapies aimed at treating the basic defect... - The clinical approach to lung disease in patients with cystic fibrosisBrian P O'Sullivan
Department of Pediatrics, University of Massachusetts Medical School, Worcester, Massachusetts 01655, USA
Semin Respir Crit Care Med 30:505-13. 2009..Empowering patients in the process of providing their own care is a key to achieving this goal... - Inhaled aztreonamBrian P O'Sullivan
Brian P O Sullivan is at the University of Massachusetts Memorial Medical Center, 55 Lake Avenue Worcester, Massachusetts 01655, USA
Nat Rev Drug Discov 9:357-8. 2010.... - Use of nasopharyngoscopy in the evaluation of children with noisy breathingBrian P O'Sullivan
Department of Pediatrics, University of Massachusetts Medical School, UMass Memorial Health Care, Worcester, MA 01655, USA
Chest 125:1265-9. 2004..To evaluate the practice of using nasopharyngoscopy without routine fiberoptic bronchoscopy for children presenting to a pediatric pulmonary practice with nonspecific noisy breathing... - The inflammatory role of platelets in cystic fibrosisBrian P O'Sullivan
Department of Pediatrics, UMass Memorial Health Care, 55 Lake Avenue, North Worcester, MA 01655, USA
Am J Respir Crit Care Med 173:483-90. 2006..We hypothesize that platelet activation is important in CF lung disease and suggest research avenues that might help elucidate the role of activated platelets in CF... - Burkholderia pseudomallei infection in a child with cystic fibrosis: acquisition in the Western HemisphereBrian P O'Sullivan
Department of Pediatrics, University of Massachusetts Medical School and UMass Memorial Health Care, Worcester, MA 01655, USA
Chest 140:239-42. 2011.... - Early pulmonary manifestation of cystic fibrosis in children with the DeltaF508/R117H-7T genotypeBrian P O'Sullivan
Department of Pediatrics, University of Massachusetts Medical School, Worcester, Massachusetts 01655, USA
Pediatrics 118:1260-5. 2006..Our cases highlight the importance of considering keeping so-called mild mutations on cystic fibrosis newborn screening panels and the need to follow children with these mutations closely... - Baseline characteristics and factors associated with nutritional and pulmonary status at enrollment in the cystic fibrosis EPIC observational cohortMargaret Rosenfeld
Department of Pediatrics, Seattle Children s Hospital and University of Washington, Seattle, Washington, USA
Pediatr Pulmonol 45:934-44. 2010..The EPIC Observational Study is an ongoing prospective cohort study investigating risk factors for and clinical outcomes associated with early Pseudomonas aeruginosa (Pa) acquisition in young children with cystic fibrosis (CF)... - Oropharyngeal flora in healthy infants: observations and implications for cystic fibrosis careDavid Carlson
Department of Pediatrics, University of Massachusetts Medical School and UMass Memorial Health Care, Worcester, Massachusetts, USA
Pediatr Pulmonol 44:497-502. 2009..The purpose of this preliminary study was to determine normal oropharyngeal flora in healthy, non-CF infants in order to help care givers better interpret culture results obtained from infants with CF... - Platelet-monocyte aggregates in patients with chronic venous insufficiency remain elevated following correction of refluxMichael J Rohrer
Division of Vascular Surgery and the Center for Platelet Function Studies, The University of Massachusetts Medical School, 55 Lake Avenue, North Worcester 01655, USA
Cardiovasc Surg 10:464-9. 2002..The purpose of this study was to determine whether patients with CVI maintain elevated levels of PMAs following complete surgical correction of chronic venous insufficiency... - Using hyperpolarized 3He MRI to evaluate treatment efficacy in cystic fibrosis patientsYanping Sun
Department of Radiology, University of Massachusetts Medical School, Worcester, Massachusetts, USA
J Magn Reson Imaging 34:1206-11. 2011..To use hyperpolarized (HP) (3)He MR imaging to assess functional lung ventilation in subjects with cystic fibrosis (CF) before and after treatment... - Immunophenotypic analysis of plateletsLori A Krueger
University of Massachusetts Medical School, Worcester, Massachusetts, USA
Curr Protoc Cytom . 2002..Detailed discussion of appropriate sample handling, reagent preparation, flow cytometric set-up, and data interpretation are provided for three independent assays... - Residual arachidonic acid-induced platelet activation via an adenosine diphosphate-dependent but cyclooxygenase-1- and cyclooxygenase-2-independent pathway: a 700-patient study of aspirin resistanceAndrew L Frelinger
Center for Platelet Function Studies, Department of Pediatrics, UMass Memorial Medical Center, 55 Lake Ave N, Worcester, Massachusetts 01655, USA
Circulation 113:2888-96. 2006.... - Whole blood analysis of leukocyte-platelet aggregatesMarc R Barnard
University of Massachusetts Medical School, Worcester, Massachusetts, USA
Curr Protoc Cytom . 2003..Light scatter and at least one leukocyte-specific antibody are used to gate the desired population, and the presence of associated platelets is detected by immunostaining for abundant platelet-specific markers... - Release of soluble CD40L from platelets is regulated by glycoprotein IIb/IIIa and actin polymerizationMark I Furman
Center for Platelet Function Studies, University of Massachusetts Medical School, Worcester, Massachusetts 01655, USA
J Am Coll Cardiol 43:2319-25. 2004..In addition to their well-characterized inhibition of platelet aggregation, GP IIb/IIIa antagonists may obviate the proinflammatory and prothrombotic effects of sCD40L... - Spirochete-platelet attachment and thrombocytopenia in murine relapsing fever borreliosisKishore R Alugupalli
Department of Molecular Genetics and Microbiology, University of Massachusetts Medical School, 55 Lake Ave N, Worcester, MA 01655, USA
Blood 102:2843-50. 2003..These findings suggest that thrombocytopenia of relapsing fever is the result of platelet clearance after beta 3-independent bacterial attachment to circulating platelets... - The platelet hyporeactivity of extremely low birth weight neonates is age-dependentFrancis J Bednarek
Neonatology, Department of Pediatrics, University of Massachusetts Medical School and UMass Memorial Health Care, Worcester, MA 01655, USA
Thromb Res 124:42-5. 2009..The purpose of this study was to examine the age dependency of this hyporeactivity... - Combined effects of mild hypothermia and glycoprotein IIb/IIIa antagonists on platelet-platelet and leukocyte-platelet aggregationAndrew L Frelinger
Center for Platelet Function Studies, Department of Pediatrics, University of Massachusetts Medical School, Worcester 01655, USA
Am J Cardiol 92:1099-101. 2003.... - Application of flow cytometry to platelet disordersMatthew D Linden
Center for Platelet Function Studies, University of Massachusetts Medical School, Worcester, MA 01655, USA
Semin Thromb Hemost 30:501-11. 2004..Accordingly, this review summarizes the key technical and methodologic components of flow cytometric analysis of platelets, as well as specific examples of its application to diagnosis and patient care... - The active metabolite of prasugrel inhibits ADP-stimulated thrombo-inflammatory markers of platelet activation: Influence of other blood cells, calcium, and aspirinAndrew L Frelinger
Center for Platelet Function Studies, University of Massachusetts Medical School, 55 Lake Avenue North, Worcester, MA 01655, USA
Thromb Haemost 98:192-200. 2007..This inhibition is enhanced in the presence other blood cells and calcium, but not aspirin... - Methods for the measurement of platelet functionAlan D Michelson
Center for Platelet Function Studies, University of Massachusetts Medical School, Worcester, Massachusetts, USA
Am J Cardiol 103:20A-26A. 2009..Some of the factors that differentiate these tests are sample volume requirements, the use of whole blood, the presence of shear, point-of-care status, need for a technician, and expense... - Agonist and antagonist effects of diadenosine tetraphosphate, a platelet dense granule constituent, on platelet P2Y1, P2Y12 and P2X1 receptorsHung Chang
Center for Platelet Function Studies, Department of Pediatrics, University of Massachusetts Medical School, Worcester, MA, USA
Thromb Res 125:159-65. 2010..Diadenosine 5',5'''-P(1),P(4)- tetraphosphate (Ap(4)A) is stored in platelet dense granules, but its effects on platelet function are not well understood... - Platelet reactivity and the identification of acute coronary syndromes in the emergency departmentChad E Darling
Department of Emergency Medicine, University of Massachusetts Medical School, Worcester, MA 01655, USA
J Thromb Thrombolysis 28:31-7. 2009..This review will focus on selected tests/markers of platelet function that have shown some promise with respect to the risk stratification of patients with potential ACS... - Dosing of clopidogrel for platelet inhibition in infants and young children: primary results of the Platelet Inhibition in Children On cLOpidogrel (PICOLO) trialJennifer S Li
Division of Pediatric Cardiology, Department of Pediatrics, Duke University Medical Center and Duke Clinical Research Institute, Durham, NC 27705, USA
Circulation 117:553-9. 2008.... - P2Y12 antagonism: promises and challengesAlan D Michelson
Center for Platelet Function Studies, University of Massachusetts Medical School, Room S5 846, 55 Lake Avenue North, Worcester, MA 01655, USA
Arterioscler Thromb Vasc Biol 28:s33-8. 2008..Whether this promise will be translated into clinical benefit for patients will be determined by the results of ongoing phase 3 clinical trials... - Platelet function testing in cardiovascular diseasesAlan D Michelson
Center for Platelet Function Studies, Department of Pediatrics, University of Massachusetts Medical School, Worcester, Mass 01655, USA
Circulation 110:e489-93. 2004 - Aspirin resistanceAlan D Michelson
Department of Pediatrics, Center for Platelet Function Studies, University of Massachusetts Medical School, Worcester, 01655, USA
Pathophysiol Haemost Thromb 35:5-9. 2006 - Evaluation of platelet function by flow cytometryAlan D Michelson
Department of Pediatrics, Center for Platelet Function Studies, University of Massachusetts Medical School, Worcester, 01655, USA
Pathophysiol Haemost Thromb 35:67-82. 2006 - Current options in platelet function testingAlan D Michelson
Center for Platelet Function Studies, Division of Cardiovascular Medicine, Department of Pediatrics and Department of Medicine, University of Massachusetts Medical School, Worcester, Massachusetts 01655, USA
Am J Cardiol 98:4N-10N. 2006..In patients treated with antiplatelet drugs, the degree of platelet inhibition, as determined by several of these new platelet function assays, has been shown to predict major adverse cardiac events... - How platelets work: platelet function and dysfunctionAlan D Michelson
Center for Platelet Function Studies, Department of Pediatrics, University of Massachusetts Medical School, Worcester, MA 01655, USA
J Thromb Thrombolysis 16:7-12. 2003..This article briefly reviews (a) how platelets normally function and (b) the clinical approach to disorders of platelet numbers and function... - Quantification of abciximab-induced platelet inhibition is assay dependent: a comparative study in patients undergoing percutaneous coronary interventionMark I Furman
Center for Platelet Function Studies and Division of Cardiovascular Medicine, Department of Medicine, University of Massachusetts Medical School, Worcester, MA 01655, USA
Am Heart J 145:e6. 2003.... - Survey of breast-feeding practices and outcomes in the cystic fibrosis populationEliza M Parker
Department of Pediatrics, University of Massachusetts Medical School and UMass Memorial Health Care, Worcester, Massachusetts 01655, USA
Pediatr Pulmonol 37:362-7. 2004..This survey indicates that breast-feeding is not harmful to children with CF, and may be beneficial... - Effects of physiologic agonists on canine whole blood flow cytometry assays of leukocyte-platelet aggregation and platelet activationInge Tarnow
Department of Basic Animal and Veterinary Sciences, Faculty of Life Sciences, University of Copenhagen, 7 Grønnegaardsvej, DK 1870 Frederiksberg C, Denmark
Vet Immunol Immunopathol 123:345-52. 2008..In conclusion, we have developed flow cytometry assays to measure LPAs and platelet activation in canine whole blood, and have explored the effect of various physiologic agonists at different concentrations... - Effect of adenosine A2 receptor stimulation on platelet activation-aggregation: differences between canine and human modelsMatthew D Linden
Center for Platelet Function Studies, University of Massachusetts Medical School, Worcester MA 01655, United States
Thromb Res 121:689-98. 2008.... - The Ultegra rapid platelet-function assay: comparison to standard platelet function assays in patients undergoing percutaneous coronary intervention with abciximab therapyGuy L Wheeler
Wake Forest University School of Medicine, Winston-Salem, NC 27157-1045, USA
Am Heart J 143:602-11. 2002..Ultegra RPFA measurements are not operator-dependent and are not influenced by concomitant medications, hematologic parameters, or demographics... - Neonatal platelet functionSara J Israels
Department of Pediatrics and Child Health University of Manitoba, Winnipeg, Manitoba, Canada
Semin Thromb Hemost 29:363-72. 2003..In the immediate newborn period, this enhanced platelet adhesion may compensate for the decreased intrinsic platelet activation in healthy neonates, but may leave sick neonates at increased risk of bleeding... - Clopidogrel linking evaluation of platelet response variability to mechanism of actionAndrew L Frelinger
J Am Coll Cardiol 46:646-7. 2005 - Aspirin resistance and its implications in clinical practiceJohn Eikelboom
McMaster University, Hamilton, Ontario, Canada
MedGenMed 7:76. 2005.... - Antiplatelet therapy in childrenSara J Israels
Department of Pediatrics and Child Health, and the Manitoba Institute of Cell Biology, University of Manitoba, Winnipeg, Manitoba, Canada R3E 0V9
Thromb Res 118:75-83. 2006..Additional studies will be required to evaluate the relative benefits of aspirin and anticoagulants in these settings. A role for newer antiplatelet drugs in the management of pediatric arterial thrombosis is as yet unexplored... - Platelet activation and progression to complicationsDean J Kereiakes
Heart Center of Greater Cincinnati and Lindner Center at Christ Hospital, Cincinnati, Ohio, USA
Rev Cardiovasc Med 7:75-81. 2006..In general, optimal periprocedural outcomes require high levels of platelet inhibition. Combined administration of antiplatelet therapies may produce additive or synergistic inhibition of platelet-mediated thrombosis... - Therapeutic goals for effective platelet inhibition: a consensus documentStephen D Wiviott
Cardiovascular Division, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA
Rev Cardiovasc Med 7:214-25. 2006..These novel agents such as prasugrel, AZD6140, and cangrelor are in advanced stages of clinical development for potential use in patients with coronary artery disease... - Measuring antiplatelet drug effects in the laboratoryPaul Harrison
Oxford Haemophilia Centre and Thrombosis Unit, Churchill Hospital, Oxford, United Kingdom
Thromb Res 120:323-36. 2007..A clinically meaningful definition of "resistance" to antiplatelet drugs needs to be developed, based on data linking drug-dependent laboratory tests to clinical outcomes in patients... - Prasugrel compared with high loading- and maintenance-dose clopidogrel in patients with planned percutaneous coronary intervention: the Prasugrel in Comparison to Clopidogrel for Inhibition of Platelet Activation and Aggregation-Thrombolysis in MyocardialStephen D Wiviott
Brigham and Women s Hospital, Cardiovascular Division, 75 Francis St, Boston, MA 02115, USA
Circulation 116:2923-32. 2007..The relative antiplatelet effects of prasugrel versus high-dose clopidogrel in percutaneous coronary intervention patients are unknown... - An additional mechanism of action of abciximab: dispersal of newly formed platelet aggregatesStanley J Marciniak
Centocor, Malvern, PA 19355, USA
Thromb Haemost 87:1020-5. 2002..In vivo, abciximab may destabilize coronary thrombi by preventing aggregate formation and dispersing mural thrombi...